AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
10 June 2013 | By AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Pearl Therapeutics...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
10 June 2013 | By AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Pearl Therapeutics...
4 June 2013 | By Bristol-Myers Squibb Company
Metreleptin, an investigational agent for treatment of metabolic disorders associated with rare forms of LD...
4 June 2013 | By AstraZeneca
AstraZeneca announced top-line results from OSKIRA-2 and OSKIRA-3...
3 June 2013 | By AstraZeneca
AstraZeneca enters new agreement...
28 May 2013 | By AstraZeneca
AstraZeneca announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals...
16 May 2013 | By AstraZeneca
First patient enrolled in Phase III clinical trial...
23 April 2013 | By Alchemia Limited
Alchemia has signed a multi-target, drug discovery collaboration with AstraZeneca...
22 April 2013 | By AstraZeneca
“We are excited to grow this collaboration..."
5 April 2013 | By AstraZeneca
AstraZeneca announced top-line results of OSKIRA-1...
3 April 2013 | By AstraZeneca
AstraZeneca announced that MedImmune has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company...
21 March 2013 | By AstraZeneca
AstraZeneca announced that Marc Dunoyer is to join the company...
21 March 2013 | By AstraZeneca
The Centre will be set up to conduct preclinical and clinical studies...
21 March 2013 | By AstraZeneca
Agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer...
21 March 2013 | By AstraZeneca
AstraZeneca will outline its strategy to return to growth and achieve scientific leadership...
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...